Ozlem Tureci

Ozlem Tureci co-founded BioNTech with Ugur Sahin and has been instrumental in the clinical development of the company's mRNA cancer vaccine pipeline, overseeing the translation of personalized neoantigen vaccines from concept to pivotal clinical trials. Her expertise in tumor antigen discovery and neoantigen prediction has informed the computational pipelines used to select optimal vaccine targets for individual patients. She has led the clinical strategy for combining mRNA cancer vaccines with immune checkpoint inhibitors to maximize anti-tumor immune responses.